CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Clinical Lymphoma

• Publication date

  2000-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3816/CLM.2000.N.005PMID 11707814
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo1

  2000cited by this paper
• Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice.

  1999cited by this paper
• Oligodeoxynucleotides containing CpG motifs induce IL‐12, IL‐18 and IFN‐γ production in cells from allergic individuals and inhibit IgE synthesis in vitro

  1999cited by this paper
• CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells.

  1999cited by this paper
• CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.

  1998cited by this paper
• Cyclosporin A enhances IL-12 production by CpG motifs in bacterial DNA and synthetic oligodeoxynucleotides.

  1998cited by this paper
• Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells

  1998cited by this paper
• Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor.

  1998cited by this paper
• CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity

  1997cited by this paper
• Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma.

  1997cited by this paper
• Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants

  1997cited by this paper
• Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization.

  1997cited by this paper
• Immunostimulatory DNA: Sequence‐dependent production of potentially harmful or useful cytokines

  1997cited by this paper
• Contribution of CpG motifs to the immunogenicity of DNA vaccines.

  1997cited by this paper
• Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor‐α‐mediated shock

  1997cited by this paper
• Macrophages ingest and are activated by bacterial DNA.

  1996cited by this paper
• Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.

  1996cited by this paper
• CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma.

  1996cited by this paper
• CpG motifs in bacterial DNA trigger direct B-cell activation

  1995cited by this paper
• Coley's toxins, tumor necrosis factor and cancer research: a historical perspective.

  1994cited by this paper
• DNA from Bacteria, but Not from Vertebrates, Induces Interferons, Activates Natural Killer Cells and Inhibits Tumor Growth

  1992cited by this paper
• Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA.

  1991cited by this paper
• The Classic: The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas

  1991cited by this paper
• Anti-idiotypic antibodies recognizing stable epitopes limit the emergence of idiotype variants in a murine B cell lymphoma.

  1990cited by this paper
• Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.

  1990cited by this paper
• Idiotype variants emerging after anti-idiotype monoclonal antibody therapy of a murine B cell lymphoma.

  1989cited by this paper
• Heterogeneity of a murine B cell lymphoma. Isolation and characterization of idiotypic variants.

  1988cited by this paper
• In vitro Augmentation of Natural Killer Cell Activity and Production of Interferon‐α/β and ‐γ with Deoxyribonucleic Acid Fraction from Mycobacterium bovis BCG

  1988cited by this paper
• Treatment of a murine B cell lymphoma with monoclonal antibodies and IL 2.

  1987cited by this paper
• Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants.

  1986cited by this paper
• Monoclonal Anti-Idiotype Antibodies Against the Murine B Cell Lymphoma 38C13: Characterization and Use as Probes for the Biology of the Tumor In Vivo and In Vitro

  1985cited by this paper
• Induction of secretion of IgM from cells of the B cell line 38c-13 by somatic cell hybridization.

  1979cited by this paper
• Characterization of a carcinogen‐induced murine B lymphocyte cell line of C3H/eB origin

  1977cited by this paper
• TREATMENT OF INOPERABLE MALIGNANT TUMORS WITH THE TOXINES OF ERYSIPELAS AND THE BACILLUS PRODIGIOSUS

  1894cited by this paper
• THE TREATMENT OF MALIGNAT TUMORS BY REPEATED INOCULATIONS OF ERYSIPELAS: WITH A REPORT OF TEN ORIGINAL CASES

  1893cited by this paper

• Therapeutic Monoclonal Antibodies against Cancer: Present and Future

  2023cites this paper
• Efficient co-delivery of neo-epitopes using dispersion-stable layered double hydroxide nanoparticles for enhanced melanoma immunotherapy.

  2018cites this paper
• Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application

  2017cites this paper
• Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.

  2017cites this paper
• High adjuvant activity of layered double hydroxide nanoparticles and nanosheets in anti-tumour vaccine formulations.

  2017cites this paper
• Radiation‐enhanced delivery of systemically administered amphiphilic‐CpG oligodeoxynucleotide

  2017cites this paper
• TLR9 mediates S. aureus killing inside osteoblasts via induction of oxidative stress

  2016cites this paper
• Glioma

  2015influential citation
• Polarized immune responses modulated by layered double hydroxides nanoparticle conjugated with CpG.

  2014cites this paper
• Toll-like receptor 9 in alimentary tract cancers

  2014cites this paper
• inducible gene expression, without significant toxicity - β / α interferon- rituximab in patients with non-Hodgkin lymphoma: increased Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and

  2013cites this paper
• Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma.

  2012cites this paper
• Toll-like receptor 9 agonists as cancer therapeutics

  2011cites this paper
• Molecular Analysis of Regulation of Macrophage Fcγ Receptor Function: Implications for Tumor Immunotherapy

  2011cites this paper
• PCPP (poly[di(carboxylatophenoxy)-phosphazene]) microparticles co-encapsulating ovalbumin and CpG oligo-deoxynucleotides are potent enhancers of antigen specific Th1 immune responses in mice.

  2010cites this paper
• Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy.

  2009cites this paper
• Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees.

  2009cites this paper
• Immunotherapy of cancer.

  2009cites this paper
• Lipid-based delivery of CpG oligodeoxynucleotides for cancer immunotherapy

  2009cites this paper
• Antibodies and Hematologic Malignancies

  2008cites this paper
• CpG oligodeoxynucleotides as immunotherapy in cancer.

  2008cites this paper
• CPG-7909 (PF-3512676, ProMune®): toll-like receptor-9 agonist in cancer therapy

  2007cites this paper
• Les cellules dendritiques plasmacytoïdes dans le cancer à travers le rôle de TRAIL

  2007cites this paper
• CpG oligodeoxynucleotide-induced immunity prevents growth of germinal center-derived B lymphoma cells.

  2006cites this paper
• [Cancer immunotherapy with CpG-ODN].

  2005cites this paper
• Immunothérapie des cancers par oligonucléotides immunostimulants

  2005cites this paper
• Follicular lymphoma: expanding therapeutic options.

  2005cites this paper
• Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.

  2005cites this paper
• B-Cell Lymphomas Differ in their Responsiveness to CpG Oligodeoxynucleotides

  2005cites this paper
• Immunothérapiecancers par oligonucléotides

  2005cites this paper
• Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts.

  2004cites this paper
• Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides

  2004cites this paper
• Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts.

  2004cites this paper
• Development of immunomodulatory six base-length non-CpG motif oligonucleotides for cancer vaccination.

  2004cites this paper
• Myeloid Differentiation Factor 88-dependent Post-transcriptional Regulation of Cyclooxygenase-2 Expression by CpG DNA

  2003cites this paper
• CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response

  2003cites this paper
• CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.

  2003cites this paper
• Innate immunity in breast carcinoma.

  2003cites this paper
• Endocrine-Related Cancer ( 2003 ) 10 301 – 308 Innate immunity in breast carcinoma

  2003cites this paper
• Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer.

  2003cites this paper
• CpG-oligonucleotides for cancer immunotherapy : review of the literature and potential applications in malignant glioma.

  2003cites this paper
• Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

  2003cites this paper
• Myeloid Differentiation Factor 88-dependent Transcriptional Regulation of Cyclooxygenase-2 Expression by CpG DNA

  2003cites this paper
• Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma.

  2002cites this paper
• CpG Oligodeoxynucleotides and Monoclonal Antibody Therapy of Lymphoma

  2002cites this paper
• CpG motifs in bacterial DNA and their immune effects.

  2002cites this paper
• Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma.

  2002cites this paper
• Commentary on “The History of the Development of Vaccines for the Treatment of Lymphoma”

  2000cites this paper